pharmaceutical drugs made by life sciences companies

Drug safety surveillance with third parties

Additional layers of complexity and uncertainty continue to be added to how life sciences companies bring their products to market as more stakeholders become involved in the commercialization process. While much emphasis is placed on company compliance with regulatory requirements – less emphasis has been placed on vendors or global commercial partners. By not having an established auditing, monitoring and surveillance program of third parties, an undue amount of risk and uncertainty can be imposed on drug manufacturers and their products. 

Join the Drug Information Association (DIA) and Baker Tilly for an informative presentation about drug safety governance when working with third parties. Our colleagues will discuss:

  • The components of an effective governance policy
  • The importance of having established communication channels between companies and third parties, even when stakeholder software and systems are not fully integrated
  • How to protect the value of your drug or product by managing your company’s global responsibly through vendor relationships

Who should attend

  • C-Suite, legal, regulatory affairs, medical affairs, quality and safety, internal audit, and compliance and monitoring professionals at emerging and established life sciences companies


  • Darren Jones, CIA, Principal and Life Sciences Consulting Practice Leader, Baker Tilly
  • Ashley Jones, JD, Legal Consultant, Baker Tilly

Similar events


DCAA forward pricing rate audits


Medtech reimbursement in 2021: securing coverage and payment for your innovative device


DCAA incurred cost proposal audits


Macroeconomic trend outlook and the four food groups of real estate